Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Adenosine Receptor A3 (ADORA3) - Overview
Adenosine Receptor A3 (ADORA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Neumentum Inc
Palo BioFarma SL
Protheragen Inc
Adenosine Receptor A3 (ADORA3) - Drug Profiles
Canbinoids - Drug Profile
Product Description
Mechanism Of Action
History of Events
CF-602 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DPP-017 - Drug Profile
Product Description
Mechanism Of Action
FM-1203 - Drug Profile
Product Description
Mechanism Of Action
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
History of Events
modenoson - Drug Profile
Product Description
Mechanism Of Action
History of Events
NTM-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
History of Events
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
Adenosine Receptor A3 (ADORA3) - Dormant Products
Adenosine Receptor A3 (ADORA3) - Discontinued Products
Adenosine Receptor A3 (ADORA3) - Product Development Milestones
Featured News & Press Releases
Jul 11, 2022: Can-Fite to submit FDA & EMA registration plans for piclidenoson in the oral treatment of moderate to severe psoriasis
Jun 29, 2022: Can-Fite announces positive top-line results from piclidenoson phase III COMFORT study in moderate to severe psoriasis
Jun 24, 2022: Can-Fite’s CF602 reverses erectile dysfunction in diabetic pre-clinical model: study published in peer-reviewed Jourl Andrologia
Jun 09, 2022: Can-Fite announces publication of clinical study data for piclidenoson and modenoson in scientific jourl
May 16, 2022: Can-Fite granted key SH Patent in Israel
May 02, 2022: Can-Fite’s CEO to present modenoson’s efficacy in liver cancer as expert speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
Apr 05, 2022: Can-Fite is developing a topical Piclidenoson psoriasis treatment that shows efficacy in a preclinical model: potential complementary product to its phase III oral psoriasis drug
Mar 28, 2022: Can-Fite to present at Dermatology Drug Development Summit Europe on April 6, 2022
Mar 14, 2022: Can-Fite: modenoson’s treatment of liver fibrosis receives Notice of Allowance from U.S. Patent Office
Mar 08, 2022: Can-Fite’s phase III psoriasis study data expected Q2 2022
Feb 01, 2022: Can-Fite enrols first subject in Phase IIb SH trial
Jan 13, 2022: Prior to phase III psoriasis data release Can Fite reports that piclidenoson destroys pathological skin cells in vitro
Jan 10, 2022: Can-Fite to conduct investor meetings during the J.P. Morgan Healthcare Conference
Dec 29, 2021: Following complete clearance of cancer lesions in advanced liver cancer patient, Can-Fite is filing patent applications for the treatment of various advanced solid tumors
Dec 20, 2021: Liver cancer patient treated with Can-Fite’s modenoson clears all cancer lesions under open label extension of phase II Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Can-Fite BioPharma Ltd, 2022
Pipeline by Future Medicine Co Ltd, 2022
Pipeline by Neumentum Inc, 2022
Pipeline by Palo BioFarma SL, 2022
Pipeline by Protheragen Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022